Publications by authors named "Keith D Kaufman"

Claim this Profile
S
Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1.
Sharon L Hillier, Linda-Gail Bekker, Sharon A Riddler, Craig W Hendrix, Sharlaa Badal-Faesen, Keith D Kaufman

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH.
Annaswamy Raji, Ira Gantz, Michael Crutchlow, Heather Flynn, Lianzhe Xu, Keith D Kaufman

Aliment Pharmacol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Manuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, Eirum Chaudhri, Jie Liu, Keith D Kaufman

J Hepatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism.
R Ravi Shankar, Suneri Shah, Hee-Koung Joeng, Geraldine Mendizabal, Julia R DiBello, Keith D Kaufman

J Clin Endocrinol Metab· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
R Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Keith D Kaufman

Pediatr Diabetes· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Muhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S Newfield, Keith D Kaufman

Pediatr Diabetes· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
Abhinav Sharma, Yinggan Zheng, Justin A Ezekowitz, Cynthia M Westerhout, Jacob A Udell, Keith D Kaufman

Diabetes Care· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Kohei Kaku, Takashi Kadowaki, Yutaka Seino, Taro Okamoto, Masayoshi Shirakawa, Keith D Kaufman

Diabetes Obes Metab· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Yutaka Seino, Kohei Kaku, Takashi Kadowaki, Taro Okamoto, Asako Sato, Keith D Kaufman

Diabetes Obes Metab· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency.
Annaswamy Raji, Zhi Jin Xu, Raymond L H Lam, Edward A O'Neill, Keith D Kaufman

Diabetes Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
Michael R McClung, Michelle L O'Donoghue, Socrates E Papapoulos, Henry Bone, Bente Langdahl, Keith D Kaufman

Lancet Diabetes Endocrinol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Juan P Frias, Zachary Zimmer, Raymond L H Lam, Guillermo Amorin, Catherine Ntabadde, Keith D Kaufman

Diabetes Obes Metab· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Ronan Roussel, Santiago Duran-García, Yilong Zhang, Suneri Shah, Carolyn Darmiento, Keith D Kaufman

Diabetes Obes Metab· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Russell Scott, Jerry Morgan, Zachary Zimmer, Raymond L H Lam, Edward A O'Neill, Keith D Kaufman

Diabetes Obes Metab· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Shelby D Reed, Yanhong Li, Jose Leal, Larry Radican, Amanda I Adler, Keith D Kaufman

Diabetes Obes Metab· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Philip Home, R Ravi Shankar, Ira Gantz, Carol Iredale, Edward A O'Neill, Keith D Kaufman

Diabetes Res Clin Pract· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Abhinav Sharma, Jennifer B Green, Allison Dunning, Yuliya Lokhnygina, Sana M Al-Khatib, Keith D Kaufman

Diabetes Care· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A O'Neill, Keith D Kaufman

Diabetes Obes Metab· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A O'Neill, Keith D Kaufman

BMC Endocr Disord· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
R Ravi Shankar, Silvio E Inzucchi, Victoria Scarabello, Ira Gantz, Keith D Kaufman

Curr Med Res Opin· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Yehuda Handelsman, Brett Lauring, Ira Gantz, Carol Iredale, Edward A O'Neill, Keith D Kaufman

Curr Med Res Opin· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Ira Gantz, Liubov Sokolova, Lokesh Jain, Carol Iredale, Edward A O'Neill, Keith D Kaufman

Clin Ther· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Catherine Ntabadde, Sukrut Shah, Keith D Kaufman

Cardiovasc Diabetol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
M Angelyn Bethel, Samuel S Engel, Jennifer B Green, Zhen Huang, Robert G Josse, Keith D Kaufman

Diabetes Care· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Ronald Goldenberg, Ira Gantz, Paula J Andryuk, Edward A O'Neill, Keith D Kaufman

Diabetes Obes Metab· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis